# I06 — PYDANTIC_CONDITIONAL_CRITIC — COMMON_TRANSCRIPT T2

## INPUT

Message utilisateur courant VERBATIM :

> Pour la comparaison DSC-ASL il faut les deux, mais les patients ASL-only peuvent rester dans une analyse secondaire. Je ne sais pas encore laquelle doit être la mesure principale.

Conversation précédente VERBATIM :

> I06:T0 | USER : Je compare DSC et ASL chez mes gliomes. Quand elles ne racontent pas la même chose, je veux savoir laquelle est la plus utile pour la progression. Pour ceux qui n'ont que la seconde, je préfère quand même les garder si c'est possible.
> I06:R1 | USER : Par \"la seconde\", je parle de l'ASL. Je veux distinguer progression vraie et pseudoprogression à 3 mois.

## NATIVE OUTPUT

Artefact : `experiments/semantic-engine-comparison/results/common-contract-ablation-02/native-outputs/common-transcript-i06-t2-pydantic-conditional-critic.json`

```json
{
  "criticOutput": {
    "correctedState": {
      "ambiguities": [
        {
          "ambiguityId": "amb_primary_measure",
          "content": "It is not yet decided whether DSC or ASL should be the primary measurement/modality for the analysis.",
          "decisionImpact": "Can change the principal endpoint, primary analytical weight, and main decision strategy between DSC and ASL.",
          "epistemicStatus": "AMBIGUOUS",
          "interpretations": [
            "DSC as primary measurement",
            "ASL as primary measurement"
          ],
          "provenanceTurnIds": [
            "I06:R2"
          ]
        }
      ],
      "clarificationCandidates": [
        {
          "blocking": false,
          "clarificationId": "clar_primary_measure",
          "decisionImpact": "Will determine the primary analytical endpoint and main modality focus between DSC and ASL.",
          "priority": "MEDIUM",
          "question": "Souhaitez-vous privilégier DSC ou ASL comme mesure principale pour cette étude ?",
          "targetIds": [
            "amb_primary_measure"
          ]
        }
      ],
      "contextualScientificCandidates": [],
      "contradictions": [],
      "conversationTurns": [
        {
          "content": "Je compare DSC et ASL chez mes gliomes. Quand elles ne racontent pas la même chose, je veux savoir laquelle est la plus utile pour la progression. Pour ceux qui n'ont que la seconde, je préfère quand même les garder si c'est possible.",
          "role": "USER",
          "turnId": "I06:T0"
        },
        {
          "content": "Par \\\"la seconde\\\", je parle de l'ASL. Je veux distinguer progression vraie et pseudoprogression à 3 mois.",
          "role": "USER",
          "turnId": "I06:R1"
        },
        {
          "content": "Pour la comparaison DSC-ASL il faut les deux, mais les patients ASL-only peuvent rester dans une analyse secondaire. Je ne sais pas encore laquelle doit être la mesure principale.",
          "role": "USER",
          "turnId": "I06:R2"
        }
      ],
      "correctionsAndSupersessions": [
        {
          "correctionId": "corr_second_modality",
          "currentContent": "ASL",
          "disposition": "CONFIRMED",
          "previousContent": "la seconde",
          "provenanceTurnIds": [
            "I06:R1"
          ]
        }
      ],
      "explicitUserStatements": [
        {
          "basis": null,
          "content": "Je compare DSC et ASL chez mes gliomes.",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "itemId": "stmt_compare_dsc_asl",
          "ownership": "USER",
          "polarity": "AFFIRMED",
          "provenanceTurnIds": [
            "I06:T0"
          ],
          "scientificRole": "comparative_analysis",
          "sourceText": "Je compare DSC et ASL chez mes gliomes.",
          "temporalContext": null
        },
        {
          "basis": null,
          "content": "Quand elles ne racontent pas la même chose, je veux savoir laquelle est la plus utile pour la progression.",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "itemId": "stmt_discrepancy_utility",
          "ownership": "USER",
          "polarity": "AFFIRMED",
          "provenanceTurnIds": [
            "I06:T0"
          ],
          "scientificRole": "endpoint_or_goal",
          "sourceText": "Quand elles ne racontent pas la même chose, je veux savoir laquelle est la plus utile pour la progression.",
          "temporalContext": null
        },
        {
          "basis": null,
          "content": "Pour ceux qui n'ont que la seconde, je préfère quand même les garder si c'est possible.",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "itemId": "stmt_keep_second_only",
          "ownership": "USER",
          "polarity": "AFFIRMED",
          "provenanceTurnIds": [
            "I06:T0"
          ],
          "scientificRole": "cohort_inclusion_preference",
          "sourceText": "Pour ceux qui n'ont que la seconde, je préfère quand même les garder si c'est possible.",
          "temporalContext": null
        },
        {
          "basis": null,
          "content": "Par 'la seconde', je parle de l'ASL.",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "itemId": "stmt_clarify_second",
          "ownership": "USER",
          "polarity": "AFFIRMED",
          "provenanceTurnIds": [
            "I06:R1"
          ],
          "scientificRole": "method_definition",
          "sourceText": "Par \\\"la seconde\\\", je parle de l'ASL.",
          "temporalContext": null
        },
        {
          "basis": null,
          "content": "Je veux distinguer progression vraie et pseudoprogression à 3 mois.",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "itemId": "stmt_distinguish_progression",
          "ownership": "USER",
          "polarity": "AFFIRMED",
          "provenanceTurnIds": [
            "I06:R1"
          ],
          "scientificRole": "endpoint_definition",
          "sourceText": "Je veux distinguer progression vraie et pseudoprogression à 3 mois.",
          "temporalContext": "3 mois"
        },
        {
          "basis": null,
          "content": "Pour la comparaison DSC-ASL il faut les deux, mais les patients ASL-only peuvent rester dans une analyse secondaire.",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "itemId": "stmt_comparison_and_secondary",
          "ownership": "USER",
          "polarity": "AFFIRMED",
          "provenanceTurnIds": [
            "I06:R2"
          ],
          "scientificRole": "analysis_design",
          "sourceText": "Pour la comparaison DSC-ASL il faut les deux, mais les patients ASL-only peuvent rester dans une analyse secondaire.",
          "temporalContext": null
        },
        {
          "basis": null,
          "content": "Je ne sais pas encore laquelle doit être la mesure principale.",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "itemId": "stmt_unknown_primary_measure",
          "ownership": "USER",
          "polarity": "AFFIRMED",
          "provenanceTurnIds": [
            "I06:R2"
          ],
          "scientificRole": "decision_status",
          "sourceText": "Je ne sais pas encore laquelle doit être la mesure principale.",
          "temporalContext": null
        }
      ],
      "inferredContext": [],
      "missingInformation": [],
      "negationsAndConstraints": [],
      "normalizedUnderstanding": "The user is comparing DSC and ASL perfusion methods in glioma patients at 3 months to distinguish true progression from pseudoprogression. When DSC and ASL results diverge, the user aims to determine which modality is more useful for progression. Patients with both modalities are required for the main comparative analysis, whereas ASL-only patients should be retained in a secondary analysis. The primary measurement modality between DSC and ASL remains undecided.",
      "objects": [
        {
          "basis": null,
          "content": "DSC",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "itemId": "obj_dsc",
          "ownership": "USER",
          "polarity": "AFFIRMED",
          "provenanceTurnIds": [
            "I06:T0"
          ],
          "scientificRole": "method",
          "sourceText": "DSC",
          "temporalContext": null
        },
        {
          "basis": null,
          "content": "ASL",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "itemId": "obj_asl",
          "ownership": "USER",
          "polarity": "AFFIRMED",
          "provenanceTurnIds": [
            "I06:T0",
            "I06:R1"
          ],
          "scientificRole": "method",
          "sourceText": "ASL",
          "temporalContext": null
        },
        {
          "basis": null,
          "content": "gliomes",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "itemId": "obj_gliomas",
          "ownership": "USER",
          "polarity": "AFFIRMED",
          "provenanceTurnIds": [
            "I06:T0"
          ],
          "scientificRole": "population",
          "sourceText": "gliomes",
          "temporalContext": null
        },
        {
          "basis": null,
          "content": "progression vraie et pseudoprogression à 3 mois",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "itemId": "obj_progression_endpoint",
          "ownership": "USER",
          "polarity": "AFFIRMED",
          "provenanceTurnIds": [
            "I06:R1"
          ],
          "scientificRole": "endpoint",
          "sourceText": "progression vraie et pseudoprogression à 3 mois",
          "temporalContext": "3 mois"
        }
      ],
      "originalRequest": "I06:T0 | USER: Je compare DSC et ASL chez mes gliomes. Quand elles ne racontent pas la même chose, je veux savoir laquelle est la plus utile pour la progression. Pour ceux qui n'ont que la seconde, je préfère quand même les garder si c'est possible.",
      "ownershipAndEpistemicState": [
        {
          "content": "Comparison of DSC and ASL in gliomas",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "owner": "USER",
          "provenanceTurnIds": [],
          "statementId": "stmt_compare_dsc_asl"
        },
        {
          "content": "Utility for progression when modalities diverge",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "owner": "USER",
          "provenanceTurnIds": [],
          "statementId": "stmt_discrepancy_utility"
        },
        {
          "content": "Preference to keep ASL-only patients",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "owner": "USER",
          "provenanceTurnIds": [],
          "statementId": "stmt_keep_second_only"
        },
        {
          "content": "Distinguishing true progression from pseudoprogression at 3 months",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "owner": "USER",
          "provenanceTurnIds": [],
          "statementId": "stmt_distinguish_progression"
        },
        {
          "content": "DSC-ASL comparison requires both; ASL-only patients in secondary analysis",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "owner": "USER",
          "provenanceTurnIds": [],
          "statementId": "stmt_comparison_and_secondary"
        },
        {
          "content": "Primary measurement modality not yet decided",
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "owner": "USER",
          "provenanceTurnIds": [],
          "statementId": "stmt_unknown_primary_measure"
        }
      ],
      "relations": [
        {
          "basis": null,
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "object": "obj_asl",
          "ownership": "USER",
          "polarity": "AFFIRMED",
          "predicate": "is_clarified_as",
          "provenanceTurnIds": [
            "I06:R1"
          ],
          "relationId": "rel_second_is_asl",
          "sourceText": "Par \\\"la seconde\\\", je parle de l'ASL.",
          "subject": "stmt_keep_second_only",
          "temporalContext": null
        },
        {
          "basis": null,
          "epistemicStatus": "EXPLICIT_USER_STATED",
          "object": "obj_progression_endpoint",
          "ownership": "USER",
          "polarity": "AFFIRMED",
          "predicate": "targets_endpoint",
          "provenanceTurnIds": [
            "I06:R1"
          ],
          "relationId": "rel_endpoint_target",
          "sourceText": "Je veux distinguer progression vraie et pseudoprogression à 3 mois.",
          "subject": "stmt_discrepancy_utility",
          "temporalContext": "3 mois"
        }
      ],
      "scientificGoal": "Determine the relative clinical utility of DSC versus ASL perfusion in glioma progression assessment (distinguishing true progression from pseudoprogression at 3 months), incorporating both comparative analyses and secondary analyses for single-modality ASL patients.",
      "temporalModel": [],
      "unknowns": []
    },
    "rationale": "The state correctly captures all explicit statements, user ownership, conversational turns, ambiguities, and relations without any fidelity or structural errors.",
    "verdict": "ACCEPT"
  },
  "criticTrigger": {
    "reasons": [
      "AMBIGUITIES_PRESENT",
      "CORRECTIONS_OR_SUPERSESSIONS_PRESENT"
    ],
    "required": true
  },
  "firstOutput": {
    "ambiguities": [
      {
        "ambiguityId": "amb_primary_measure",
        "content": "It is not yet decided whether DSC or ASL should be the primary measurement/modality for the analysis.",
        "decisionImpact": "Can change the principal endpoint, primary analytical weight, and main decision strategy between DSC and ASL.",
        "epistemicStatus": "AMBIGUOUS",
        "interpretations": [
          "DSC as primary measurement",
          "ASL as primary measurement"
        ],
        "provenanceTurnIds": [
          "I06:R2"
        ]
      }
    ],
    "clarificationCandidates": [
      {
        "blocking": false,
        "clarificationId": "clar_primary_measure",
        "decisionImpact": "Will determine the primary analytical endpoint and main modality focus between DSC and ASL.",
        "priority": "MEDIUM",
        "question": "Souhaitez-vous privilégier DSC ou ASL comme mesure principale pour cette étude ?",
        "targetIds": [
          "amb_primary_measure"
        ]
      }
    ],
    "contextualScientificCandidates": [],
    "contradictions": [],
    "conversationTurns": [
      {
        "content": "Je compare DSC et ASL chez mes gliomes. Quand elles ne racontent pas la même chose, je veux savoir laquelle est la plus utile pour la progression. Pour ceux qui n'ont que la seconde, je préfère quand même les garder si c'est possible.",
        "role": "USER",
        "turnId": "I06:T0"
      },
      {
        "content": "Par \"la seconde\", je parle de l'ASL. Je veux distinguer progression vraie et pseudoprogression à 3 mois.",
        "role": "USER",
        "turnId": "I06:R1"
      },
      {
        "content": "Pour la comparaison DSC-ASL il faut les deux, mais les patients ASL-only peuvent rester dans une analyse secondaire. Je ne sais pas encore laquelle doit être la mesure principale.",
        "role": "USER",
        "turnId": "I06:R2"
      }
    ],
    "correctionsAndSupersessions": [
      {
        "correctionId": "corr_second_modality",
        "currentContent": "ASL",
        "disposition": "CONFIRMED",
        "previousContent": "la seconde",
        "provenanceTurnIds": [
          "I06:R1"
        ]
      }
    ],
    "explicitUserStatements": [
      {
        "basis": null,
        "content": "Je compare DSC et ASL chez mes gliomes.",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "itemId": "stmt_compare_dsc_asl",
        "ownership": "USER",
        "polarity": "AFFIRMED",
        "provenanceTurnIds": [
          "I06:T0"
        ],
        "scientificRole": "comparative_analysis",
        "sourceText": "Je compare DSC et ASL chez mes gliomes.",
        "temporalContext": null
      },
      {
        "basis": null,
        "content": "Quand elles ne racontent pas la même chose, je veux savoir laquelle est la plus utile pour la progression.",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "itemId": "stmt_discrepancy_utility",
        "ownership": "USER",
        "polarity": "AFFIRMED",
        "provenanceTurnIds": [
          "I06:T0"
        ],
        "scientificRole": "endpoint_or_goal",
        "sourceText": "Quand elles ne racontent pas la même chose, je veux savoir laquelle est la plus utile pour la progression.",
        "temporalContext": null
      },
      {
        "basis": null,
        "content": "Pour ceux qui n'ont que la seconde, je préfère quand même les garder si c'est possible.",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "itemId": "stmt_keep_second_only",
        "ownership": "USER",
        "polarity": "AFFIRMED",
        "provenanceTurnIds": [
          "I06:T0"
        ],
        "scientificRole": "cohort_inclusion_preference",
        "sourceText": "Pour ceux qui n'ont que la seconde, je préfère quand même les garder si c'est possible.",
        "temporalContext": null
      },
      {
        "basis": null,
        "content": "Par 'la seconde', je parle de l'ASL.",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "itemId": "stmt_clarify_second",
        "ownership": "USER",
        "polarity": "AFFIRMED",
        "provenanceTurnIds": [
          "I06:R1"
        ],
        "scientificRole": "method_definition",
        "sourceText": "Par \"la seconde\", je parle de l'ASL.",
        "temporalContext": null
      },
      {
        "basis": null,
        "content": "Je veux distinguer progression vraie et pseudoprogression à 3 mois.",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "itemId": "stmt_distinguish_progression",
        "ownership": "USER",
        "polarity": "AFFIRMED",
        "provenanceTurnIds": [
          "I06:R1"
        ],
        "scientificRole": "endpoint_definition",
        "sourceText": "Je veux distinguer progression vraie et pseudoprogression à 3 mois.",
        "temporalContext": "3 mois"
      },
      {
        "basis": null,
        "content": "Pour la comparaison DSC-ASL il faut les deux, mais les patients ASL-only peuvent rester dans une analyse secondaire.",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "itemId": "stmt_comparison_and_secondary",
        "ownership": "USER",
        "polarity": "AFFIRMED",
        "provenanceTurnIds": [
          "I06:R2"
        ],
        "scientificRole": "analysis_design",
        "sourceText": "Pour la comparaison DSC-ASL il faut les deux, mais les patients ASL-only peuvent rester dans une analyse secondaire.",
        "temporalContext": null
      },
      {
        "basis": null,
        "content": "Je ne sais pas encore laquelle doit être la mesure principale.",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "itemId": "stmt_unknown_primary_measure",
        "ownership": "USER",
        "polarity": "AFFIRMED",
        "provenanceTurnIds": [
          "I06:R2"
        ],
        "scientificRole": "decision_status",
        "sourceText": "Je ne sais pas encore laquelle doit être la mesure principale.",
        "temporalContext": null
      }
    ],
    "inferredContext": [],
    "missingInformation": [],
    "negationsAndConstraints": [],
    "normalizedUnderstanding": "The user is comparing DSC and ASL perfusion methods in glioma patients at 3 months to distinguish true progression from pseudoprogression. When DSC and ASL results diverge, the user aims to determine which modality is more useful for progression. Patients with both modalities are required for the main comparative analysis, whereas ASL-only patients should be retained in a secondary analysis. The primary measurement modality between DSC and ASL remains undecided.",
    "objects": [
      {
        "basis": null,
        "content": "DSC",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "itemId": "obj_dsc",
        "ownership": "USER",
        "polarity": "AFFIRMED",
        "provenanceTurnIds": [
          "I06:T0"
        ],
        "scientificRole": "method",
        "sourceText": "DSC",
        "temporalContext": null
      },
      {
        "basis": null,
        "content": "ASL",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "itemId": "obj_asl",
        "ownership": "USER",
        "polarity": "AFFIRMED",
        "provenanceTurnIds": [
          "I06:T0",
          "I06:R1"
        ],
        "scientificRole": "method",
        "sourceText": "ASL",
        "temporalContext": null
      },
      {
        "basis": null,
        "content": "gliomes",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "itemId": "obj_gliomas",
        "ownership": "USER",
        "polarity": "AFFIRMED",
        "provenanceTurnIds": [
          "I06:T0"
        ],
        "scientificRole": "population",
        "sourceText": "gliomes",
        "temporalContext": null
      },
      {
        "basis": null,
        "content": "progression vraie et pseudoprogression à 3 mois",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "itemId": "obj_progression_endpoint",
        "ownership": "USER",
        "polarity": "AFFIRMED",
        "provenanceTurnIds": [
          "I06:R1"
        ],
        "scientificRole": "endpoint",
        "sourceText": "progression vraie et pseudoprogression à 3 mois",
        "temporalContext": "3 mois"
      }
    ],
    "originalRequest": "I06:T0 | USER: Je compare DSC et ASL chez mes gliomes. Quand elles ne racontent pas la même chose, je veux savoir laquelle est la plus utile pour la progression. Pour ceux qui n'ont que la seconde, je préfère quand même les garder si c'est possible.",
    "ownershipAndEpistemicState": [
      {
        "content": "Comparison of DSC and ASL in gliomas",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "owner": "USER",
        "provenanceTurnIds": [],
        "statementId": "stmt_compare_dsc_asl"
      },
      {
        "content": "Utility for progression when modalities diverge",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "owner": "USER",
        "provenanceTurnIds": [],
        "statementId": "stmt_discrepancy_utility"
      },
      {
        "content": "Preference to keep ASL-only patients",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "owner": "USER",
        "provenanceTurnIds": [],
        "statementId": "stmt_keep_second_only"
      },
      {
        "content": "Distinguishing true progression from pseudoprogression at 3 months",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "owner": "USER",
        "provenanceTurnIds": [],
        "statementId": "stmt_distinguish_progression"
      },
      {
        "content": "DSC-ASL comparison requires both; ASL-only patients in secondary analysis",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "owner": "USER",
        "provenanceTurnIds": [],
        "statementId": "stmt_comparison_and_secondary"
      },
      {
        "content": "Primary measurement modality not yet decided",
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "owner": "USER",
        "provenanceTurnIds": [],
        "statementId": "stmt_unknown_primary_measure"
      }
    ],
    "relations": [
      {
        "basis": null,
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "object": "obj_asl",
        "ownership": "USER",
        "polarity": "AFFIRMED",
        "predicate": "is_clarified_as",
        "provenanceTurnIds": [
          "I06:R1"
        ],
        "relationId": "rel_second_is_asl",
        "sourceText": "Par \"la seconde\", je parle de l'ASL.",
        "subject": "stmt_keep_second_only",
        "temporalContext": null
      },
      {
        "basis": null,
        "epistemicStatus": "EXPLICIT_USER_STATED",
        "object": "obj_progression_endpoint",
        "ownership": "USER",
        "polarity": "AFFIRMED",
        "predicate": "targets_endpoint",
        "provenanceTurnIds": [
          "I06:R1"
        ],
        "relationId": "rel_endpoint_target",
        "sourceText": "Je veux distinguer progression vraie et pseudoprogression à 3 mois.",
        "subject": "stmt_discrepancy_utility",
        "temporalContext": "3 mois"
      }
    ],
    "scientificGoal": "Determine the relative clinical utility of DSC versus ASL perfusion in glioma progression assessment (distinguishing true progression from pseudoprogression at 3 months), incorporating both comparative analyses and secondary analyses for single-modality ASL patients.",
    "temporalModel": [],
    "unknowns": []
  }
}
```

## STRUCTURED CONTRACT STATUS

- provider status : `SUCCESS`
- parsing status : `PARSED_AND_VALIDATED`
- structured contract conformance : `PASS`
- scientific semantic evaluability : `EVALUABLE`
- evaluation mode : `DETERMINISTIC_COMMON_STATE_PROJECTION`
- native raw output persisted : `false`

## SCIENTIFIC INTERPRETATION

### COMPRÉHENSION GLOBALE

The user is comparing DSC and ASL perfusion methods in glioma patients at 3 months to distinguish true progression from pseudoprogression. When DSC and ASL results diverge, the user aims to determine which modality is more useful for progression. Patients with both modalities are required for the main comparative analysis, whereas ASL-only patients should be retained in a secondary analysis. The primary measurement modality between DSC and ASL remains undecided.

Objectif scientifique produit :

Determine the relative clinical utility of DSC versus ASL perfusion in glioma progression assessment (distinguishing true progression from pseudoprogression at 3 months), incorporating both comparative analyses and secondary analyses for single-modality ASL patients.

### EXPLICITEMENT DIT PAR LE CHERCHEUR

- content=Je compare DSC et ASL chez mes gliomes. | scientificRole=comparative_analysis | polarity=AFFIRMED | epistemicStatus=EXPLICIT_USER_STATED | ownership=USER | sourceText=Je compare DSC et ASL chez mes gliomes. | provenanceTurnIds=["I06:T0"]
- content=Quand elles ne racontent pas la même chose, je veux savoir laquelle est la plus utile pour la progression. | scientificRole=endpoint_or_goal | polarity=AFFIRMED | epistemicStatus=EXPLICIT_USER_STATED | ownership=USER | sourceText=Quand elles ne racontent pas la même chose, je veux savoir laquelle est la plus utile pour la progression. | provenanceTurnIds=["I06:T0"]
- content=Pour ceux qui n'ont que la seconde, je préfère quand même les garder si c'est possible. | scientificRole=cohort_inclusion_preference | polarity=AFFIRMED | epistemicStatus=EXPLICIT_USER_STATED | ownership=USER | sourceText=Pour ceux qui n'ont que la seconde, je préfère quand même les garder si c'est possible. | provenanceTurnIds=["I06:T0"]
- content=Par 'la seconde', je parle de l'ASL. | scientificRole=method_definition | polarity=AFFIRMED | epistemicStatus=EXPLICIT_USER_STATED | ownership=USER | sourceText=Par \"la seconde\", je parle de l'ASL. | provenanceTurnIds=["I06:R1"]
- content=Je veux distinguer progression vraie et pseudoprogression à 3 mois. | scientificRole=endpoint_definition | polarity=AFFIRMED | temporalContext=3 mois | epistemicStatus=EXPLICIT_USER_STATED | ownership=USER | sourceText=Je veux distinguer progression vraie et pseudoprogression à 3 mois. | provenanceTurnIds=["I06:R1"]
- content=Pour la comparaison DSC-ASL il faut les deux, mais les patients ASL-only peuvent rester dans une analyse secondaire. | scientificRole=analysis_design | polarity=AFFIRMED | epistemicStatus=EXPLICIT_USER_STATED | ownership=USER | sourceText=Pour la comparaison DSC-ASL il faut les deux, mais les patients ASL-only peuvent rester dans une analyse secondaire. | provenanceTurnIds=["I06:R2"]
- content=Je ne sais pas encore laquelle doit être la mesure principale. | scientificRole=decision_status | polarity=AFFIRMED | epistemicStatus=EXPLICIT_USER_STATED | ownership=USER | sourceText=Je ne sais pas encore laquelle doit être la mesure principale. | provenanceTurnIds=["I06:R2"]

### RELATIONS COMPRISES

- subject=stmt_keep_second_only | predicate=is_clarified_as | object=obj_asl | polarity=AFFIRMED | epistemicStatus=EXPLICIT_USER_STATED | ownership=USER | sourceText=Par \"la seconde\", je parle de l'ASL. | provenanceTurnIds=["I06:R1"]
- subject=stmt_discrepancy_utility | predicate=targets_endpoint | object=obj_progression_endpoint | polarity=AFFIRMED | temporalContext=3 mois | epistemicStatus=EXPLICIT_USER_STATED | ownership=USER | sourceText=Je veux distinguer progression vraie et pseudoprogression à 3 mois. | provenanceTurnIds=["I06:R1"]

### CONTEXTE INFÉRÉ

- Aucun élément produit.

### CANDIDATS SCIENTIFIQUES CONTEXTUELS

- Aucun élément produit.

### NÉGATIONS / CONTRAINTES

- Aucun élément produit.

### TEMPORALITÉ

- Aucun élément produit.

### AMBIGUÏTÉS

- content=It is not yet decided whether DSC or ASL should be the primary measurement/modality for the analysis. | epistemicStatus=AMBIGUOUS | decisionImpact=Can change the principal endpoint, primary analytical weight, and main decision strategy between DSC and ASL. | provenanceTurnIds=["I06:R2"] | interpretations=["DSC as primary measurement", "ASL as primary measurement"]

### INFORMATIONS MANQUANTES

- Aucun élément produit.

### INCONNUES

- Aucun élément produit.

### CORRECTIONS / SUPERSESSIONS

- previousContent=la seconde | currentContent=ASL | provenanceTurnIds=["I06:R1"] | disposition=CONFIRMED

### OWNERSHIP / STATUT ÉPISTÉMIQUE

- content=Comparison of DSC and ASL in gliomas | epistemicStatus=EXPLICIT_USER_STATED | owner=USER
- content=Utility for progression when modalities diverge | epistemicStatus=EXPLICIT_USER_STATED | owner=USER
- content=Preference to keep ASL-only patients | epistemicStatus=EXPLICIT_USER_STATED | owner=USER
- content=Distinguishing true progression from pseudoprogression at 3 months | epistemicStatus=EXPLICIT_USER_STATED | owner=USER
- content=DSC-ASL comparison requires both; ASL-only patients in secondary analysis | epistemicStatus=EXPLICIT_USER_STATED | owner=USER
- content=Primary measurement modality not yet decided | epistemicStatus=EXPLICIT_USER_STATED | owner=USER

### QUESTIONS DE CLARIFICATION CANDIDATES

- question=Souhaitez-vous privilégier DSC ou ASL comme mesure principale pour cette étude ? | priority=MEDIUM | blocking=non | decisionImpact=Will determine the primary analytical endpoint and main modality focus between DSC and ASL. | targetIds=["amb_primary_measure"]

## MISSING STRUCTURAL GUARANTEES

- EXACT_PROVIDER_RAW_TEXT_NOT_PERSISTED; STRUCTURED_NATIVE_ARTIFACT_AVAILABLE

_Vue locale déterministe. Aucun appel LLM d’interprétation sémantique post-hoc._
